ArticleNature cell biology2019
Epithelial polarity limits EMT.
Article in Nature cell biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- NSUN5 Facilitates Hepatocellular Carcinoma Progression by Increasing SMAD3 Expression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Impact of HCV Infection on Hepatocyte Polarity and Plasticity.Pathogens (Basel, Switzerland) · 2022Review
- LGL1 binds to Integrin β1 and inhibits downstream signaling to promote epithelial branching in the mammary gland.Cell reports · 2022Article
- Advances in the pathogenesis and clinical application prospects of tumor biomolecules in keloid.Burns & trauma · 2022Review
- NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.Frontiers in immunology · 2022Article
- Review
- Transcriptional Control of Apical-Basal Polarity Regulators.International journal of molecular sciences · 2021Review
- RPE epithelial-mesenchymal transition plays a critical role in the pathogenesis of proliferative vitreoretinopathy.Annals of translational medicine · 2020Article
- Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer Xenografts.OncoTargets and therapy · 2020Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30824839What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.